Clinical significance
Benralizumab and mepolizumab are effective in preventing AHR in a
concentration dependent manner, with benralizumab being more potent than
mepolizumab.
At the approved doses these agents only partially inhibit the
parasympathetic hyperresponsiveness in human airways.